MY191590A - 9h-pyrrolo-dipyridine derivatives - Google Patents

9h-pyrrolo-dipyridine derivatives

Info

Publication number
MY191590A
MY191590A MYPI2017702668A MYPI2017702668A MY191590A MY 191590 A MY191590 A MY 191590A MY PI2017702668 A MYPI2017702668 A MY PI2017702668A MY PI2017702668 A MYPI2017702668 A MY PI2017702668A MY 191590 A MY191590 A MY 191590A
Authority
MY
Malaysia
Prior art keywords
pyrrolo
dipyridine
derivatives
dipyridine derivatives
radiopharmaceuticals
Prior art date
Application number
MYPI2017702668A
Other languages
English (en)
Inventor
Joel Mercier
Laurent Provins
Celine Vermeiren
Yogesh Anil Sabnis
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of MY191590A publication Critical patent/MY191590A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MYPI2017702668A 2015-02-02 2016-01-29 9h-pyrrolo-dipyridine derivatives MY191590A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15153448 2015-02-02
PCT/EP2016/051993 WO2016124508A1 (en) 2015-02-02 2016-01-29 9h-pyrrolo-dipyridine derivatives

Publications (1)

Publication Number Publication Date
MY191590A true MY191590A (en) 2022-06-30

Family

ID=52477553

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2017702668A MY191590A (en) 2015-02-02 2016-01-29 9h-pyrrolo-dipyridine derivatives

Country Status (17)

Country Link
US (3) US20180022748A1 (cg-RX-API-DMAC7.html)
EP (1) EP3253762B1 (cg-RX-API-DMAC7.html)
JP (1) JP6579670B2 (cg-RX-API-DMAC7.html)
KR (1) KR102621513B1 (cg-RX-API-DMAC7.html)
CN (1) CN107207508B (cg-RX-API-DMAC7.html)
AU (1) AU2016214537B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017016311A2 (cg-RX-API-DMAC7.html)
CA (1) CA2973648C (cg-RX-API-DMAC7.html)
CL (1) CL2017001923A1 (cg-RX-API-DMAC7.html)
DK (1) DK3253762T3 (cg-RX-API-DMAC7.html)
EA (1) EA036518B1 (cg-RX-API-DMAC7.html)
ES (1) ES2875734T3 (cg-RX-API-DMAC7.html)
IL (1) IL253381B (cg-RX-API-DMAC7.html)
MX (1) MX378155B (cg-RX-API-DMAC7.html)
MY (1) MY191590A (cg-RX-API-DMAC7.html)
SG (1) SG11201705727TA (cg-RX-API-DMAC7.html)
WO (1) WO2016124508A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2247558T (pt) 2008-02-14 2022-03-21 Lilly Co Eli Novos agentes de imagiologia para deteção de disfunção neurológica
EA036518B1 (ru) * 2015-02-02 2020-11-18 Юсб Байофарма Спрл Производные 9h-пирролодипиридина
US10835624B2 (en) * 2016-07-22 2020-11-17 Ac Immune S.A. Compounds for imaging Tau protein aggregates
EP3487545A1 (en) * 2016-07-22 2019-05-29 AC Immune S.A. Compounds for imaging tau protein aggregates
CN109689653B (zh) * 2016-09-09 2022-04-12 豪夫迈·罗氏有限公司 用于制备2-(6-硝基吡啶-3-基)-9H-二吡啶并[2,3-b;3’,4’-d]吡咯的方法
IL290809B2 (en) * 2016-11-01 2024-01-01 Arvinas Operations Inc Tau-protein targeting protacs and associated methods of use
WO2018221732A1 (ja) 2017-06-02 2018-12-06 富山化学工業株式会社 アミロイドβ蛋白質量減少剤
CA3067455C (en) 2017-06-02 2021-11-23 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating spinocerebellar ataxia
NZ759657A (en) * 2017-06-02 2022-07-29 Fujifilm Toyama Chemical Co Ltd Agent for preventing or treating tauopathy
US11541033B2 (en) 2017-06-02 2023-01-03 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating Alzheimer's disease
RU2759727C2 (ru) 2017-06-02 2021-11-17 ФУДЖИФИЛМ Тояма Кемикал Ко., Лтд. Средство для профилактики или лечения атрофии головного мозга
US11548878B2 (en) 2017-10-30 2023-01-10 Fujifilm Toyama Chemical Co., Ltd. Emopamil binding protein binding agent and use thereof
US11306089B2 (en) 2018-01-24 2022-04-19 Life Molecular Imaging Limited Gamma-carboline compounds for the detection of Tau aggregates
EP3743426A1 (en) * 2018-01-24 2020-12-02 AC Immune SA Azacarboline compounds for the detection of tau aggregates
WO2019145294A1 (en) * 2018-01-24 2019-08-01 Ac Immune Sa Novel method of preparing an imaging compound
JP7548992B2 (ja) 2019-07-17 2024-09-10 アルビナス・オペレーションズ・インコーポレイテッド タウタンパク質標的化化合物および関連する使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1268771A (en) 1968-03-15 1972-03-29 Glaxo Lab Ltd Azacarbazoles
WO2008132454A1 (en) * 2007-04-26 2008-11-06 Ge Healthcare Limited Carbolines and their use as imaging agents
PT2247558T (pt) * 2008-02-14 2022-03-21 Lilly Co Eli Novos agentes de imagiologia para deteção de disfunção neurológica
EP2370407B1 (en) * 2008-12-19 2014-06-18 Bristol-Myers Squibb Company Carbazole and carboline kinase inhibitors
CN107011342A (zh) * 2012-05-22 2017-08-04 伊莱利利公司 用于检测神经功能障碍的基于咔啉和咔唑的成像剂
US20160115162A1 (en) 2013-05-31 2016-04-28 The General Hospital Corporation Radiosynthesis of Tau Radiopharmaceuticals
CN105379130B (zh) * 2013-07-24 2017-08-22 瑞典爱立信有限公司 与无线电信号的接收有关的方法和设备
AR097931A1 (es) * 2013-10-08 2016-04-20 Hoffmann La Roche Derivados de diazacarbazol como ligandos de tau para pet
US10662193B2 (en) * 2014-01-21 2020-05-26 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins
EA036518B1 (ru) * 2015-02-02 2020-11-18 Юсб Байофарма Спрл Производные 9h-пирролодипиридина

Also Published As

Publication number Publication date
AU2016214537B2 (en) 2018-05-10
KR102621513B1 (ko) 2024-01-04
CN107207508A (zh) 2017-09-26
WO2016124508A1 (en) 2016-08-11
IL253381B (en) 2020-10-29
EA201791733A1 (ru) 2018-01-31
AU2016214537A1 (en) 2017-08-03
EP3253762B1 (en) 2021-05-05
MX378155B (es) 2025-03-10
EP3253762A1 (en) 2017-12-13
CN107207508B (zh) 2020-02-28
CA2973648A1 (en) 2016-08-11
US11312716B2 (en) 2022-04-26
US12006316B2 (en) 2024-06-11
JP2018503673A (ja) 2018-02-08
MX2017009505A (es) 2017-11-02
ES2875734T3 (es) 2021-11-11
IL253381A0 (en) 2017-09-28
KR20170113607A (ko) 2017-10-12
BR112017016311A2 (pt) 2018-03-27
US20220213103A1 (en) 2022-07-07
US20210047326A1 (en) 2021-02-18
SG11201705727TA (en) 2017-08-30
EA036518B1 (ru) 2020-11-18
CA2973648C (en) 2023-09-26
DK3253762T3 (da) 2021-07-19
US20180022748A1 (en) 2018-01-25
JP6579670B2 (ja) 2019-09-25
CL2017001923A1 (es) 2018-02-16

Similar Documents

Publication Publication Date Title
MY191590A (en) 9h-pyrrolo-dipyridine derivatives
PH12017501413A1 (en) Substituted nucleoside derivatives useful as anticancer agents
IL254124A0 (en) New 3-indole-transformed histories, medicinal preparations and methods of use
PH12017500408B1 (en) Heteroaryl compounds as btk inhibitors and uses thereof
MD20170070A2 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
MX386859B (es) Composiciones farmacéuticas sólidas de antagonistas de los receptores de andrógenos.
SG10201805628TA (en) Deuterated heterocyclic compounds and their use as imaging agents
PH12016501791A1 (en) Muscarinic receptor agonists
IL247062A0 (en) Heterocyclic compounds, their preparation and pharmaceutical preparations containing them
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
PH12015501609A1 (en) Phenicol antibacterials
TW201613864A (en) Novel compounds
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
PH12017501280A1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
PH12016501686A1 (en) Pharmaceutical compositions of sitagliptin
PH12015502632A1 (en) Cxcr7 receptor modulators
IN2014CH00840A (cg-RX-API-DMAC7.html)
MX2016003725A (es) Compuestos y su uso para la preparacion de agentes de formacion de imagen tau y formulaciones para la formacion de imagen tau.
MX371158B (es) Compuestos inhibidores de pde2.
IN2015DN02109A (cg-RX-API-DMAC7.html)
MX360040B (es) Nuevo agente antibacteriano derivado de florfenicol unido a sulfoximina y el uso del mismo en el tratamiento de infecciones bacterianas en ganado vacuno.
GB201704384D0 (en) N-((3,4,5-Trimethoxystyryl)aryl) cinnamamide compounds as potential anticancer agents and process for the preparation thereof
PL406972A1 (pl) Sposób otrzymywania kompozycji zawierającej klotrimazol oraz kompozycja farmaceutyczna uzyskana tym sposobem
MX2016015468A (es) Composiciones farmaceuticas que contienen montelukast y levocetirizina.